NDAQ:PALI - Post Discussion
Post by
whytestocks on Apr 16, 2024 12:15pm
Palisade Bio Successfully Demonstrates Bioactivation of PALI
JUST IN: $PALI Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' StoolCompany continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a bi...
PALI - Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool
Be the first to comment on this post